Omnipod Insulin Pump Sales Rise 19% in Q3
Omnipod users are seeing expanded availability, while a Class I FDA recall of certain pods was linked to 24 serious injuries.
Updated on Nov. 4, 2026 in Diabetes
Insulet reported third-quarter 2026 revenue of $842 million, up 19.2% year over year, and raised the lower end of its full-year revenue outlook, while its board approved a $1 billion share repurchase program. Results were driven by its Omnipod insulin-delivery systems, which are used by people managing diabetes.
Why it matters
Growth in Omnipod revenue reflects continued demand for tubeless insulin-delivery devices among people with diabetes in the United States and abroad. The company's stronger outlook and expanded buyback signal confidence in near-term sales of the devices that many patients rely on for daily insulin management.
The figures come from Insulet's third-quarter 2026 financial report, which compares results against prior-year revenue and analyst earnings estimates. Revenue growth was strongest internationally, at 31.7%, while Drug Delivery revenue fell 22.7% to $5.5 million.
The players
Insulet Corporation
Insulet is a medical device company known for the Omnipod tubeless insulin-delivery system used by people with type 1 and type 2 diabetes.
U.S. Food and Drug Administration
The FDA is the federal agency that regulates medical devices and classified the Omnipod pod recall as Class I, its most serious recall category.
The details
Omnipod is a tubeless insulin pump that attaches to the body and delivers insulin automatically, eliminating the need for separate tubing. The company completed the full U.S. market release of Omnipod Discover in October and expanded its U.S. sales force. The FDA has classified a recall of Omnipod pods as Class I, its most serious category, after reports linked to 24 serious injuries.
Timeline
October 2026: Full U.S. market release of Omnipod Discover completed.
Third quarter 2026: Insulet reported results that beat earnings expectations.
Fourth quarter 2026: About $400 million expected to go toward share buybacks.
2027: Omnipod 6 launch expected, with slower revenue growth anticipated.
Health Landscape
Tubeless insulin-delivery pumps like Omnipod have grown as an alternative to traditional tubed pumps for people managing insulin. This quarter's growth, paired with an FDA Class I recall of Omnipod pods, places the product line at the center of both expanding adoption and heightened safety scrutiny.
If you use an insulin pump or are considering one, the recall of Omnipod pods is worth checking against your device and discussing with your diabetes care team. Continued growth in tubeless pumps means more people may encounter these devices in routine diabetes care.
The takeaway
Anyone using an Omnipod device should check whether their pods are affected by the FDA Class I recall and talk with their clinician about any concerns. Keep your device information and recall notices handy so you can act quickly if a change is needed.
What happens next
Insulet expects to allocate approximately $400 million toward share buybacks during the fourth quarter of 2026, and expects to launch Omnipod 6 in 2027.
Further reading
For more on the devices and management strategies that shape daily life with the condition, see Diabetes coverage.
Source note: This article includes information reported by Benzinga.
